November 28, 2023

The American Society of Hematology holds a yearly conference in December to allow researchers and doctors in the blood cancer community an opportunity to...

November 15, 2023

CLL researchers found insight into one of the main causes of high-risk CLL cells multiplying quickly and a new medicine that helped stop CLL cell progression. 

November 07, 2023

Here we discuss points CLL patients can take into consideration to review if CAR T-cell therapy is right for them.

September 05, 2023

Read about why your cancer-killing immune system cells have stopped killing cancerous CLL cells and how to reverse that...

July 11, 2023

Dr. Adam Kittai shared with us at the recent ASCO 2023 conference research his team found about racial disparities. Watch his interview below...

June 23, 2023

Dr. Adam Kittai shared with us at the recent ASCO conference his research findings comparing zanubrutinib and acalabrutinib for R/R CLL. Watch the interview...

March 08, 2023

The data showed that more CLL patients were able to take acalabrutinib for a longer period of time than those taking ibrutinib.

March 02, 2023

CAR T-cell therapy is a type of immunotherapy that helps patients’ T-cells become efficient at destroying the cancer. For some CLL patients, it has cured...

March 01, 2023

CAR T-cell therapy has shown promising data to effectively treat relapsed/refractory and high-risk CLL patients. Doctor Lydia Scarfò, MD presented recent data…

February 08, 2023

There is an unmet need for high-risk CLL patients that have tried covalent followed by non-covalent BTK inhibitors and become resistant. Data gathered from...